The rationale for the use of low molecular weight heparin for hemodialysis treatments.
about
Anticoagulation for people receiving long-term haemodialysisDoes the presence of an arteriovenous fistula alter changes in body water following hemodialysis as determined by multifrequency bioelectrical impedance assessment?Considerations for Systemic Anticoagulation in ESRD.Compatibility of Injectable Anticoagulant Agents in Ethanol; In Vitro Antibiofilm Activity and Impact on Polyurethane Catheters of Enoxaparin 400 U/mL in 40% v/v Ethanol.Successful Recovery from Spontaneous Spinal Epidural Hematoma in a Patient Undergoing Hemodialysis.Association Between Low-Molecular-Weight Heparin and Risk of Bleeding Among Hemodialysis Patients: A Retrospective Cohort Study
P2860
The rationale for the use of low molecular weight heparin for hemodialysis treatments.
description
2013 nî lūn-bûn
@nan
2013 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
The rationale for the use of low molecular weight heparin for hemodialysis treatments.
@ast
The rationale for the use of low molecular weight heparin for hemodialysis treatments.
@en
type
label
The rationale for the use of low molecular weight heparin for hemodialysis treatments.
@ast
The rationale for the use of low molecular weight heparin for hemodialysis treatments.
@en
prefLabel
The rationale for the use of low molecular weight heparin for hemodialysis treatments.
@ast
The rationale for the use of low molecular weight heparin for hemodialysis treatments.
@en
P2860
P356
P1476
The rationale for the use of low molecular weight heparin for hemodialysis treatments.
@en
P2093
Andrew Davenport
P2860
P304
P356
10.1111/HDI.12086
P478
17 Suppl 1
P577
2013-10-01T00:00:00Z